Founded in 1998, it is a high-tech joint-stock enterprise integrating scientific research/development/production/sales/breeding of medicinal plants and animals
Jilin Zixin Pharmaceutical Co., Ltd., established in May 1998, is a high-tech joint-stock enterprise integrating scientific research, production, sales and breeding of medicinal plants and animals with the three major industries of Chinese patent medicine, ginseng and gene sequencer as the pillars. The company was listed on the Shenzhen Stock Exchange in March 2007 with the stock code of "002118". The company has now developed into a large-scale listed pharmaceutical group with more than 10 subsidiaries, more than 2,000 employees and a total market value of nearly 10 billion yuan. The company has been rated as "National High-tech Enterprise", "National Key Leading Enterprise of Agricultural Industrialization", "National Contract-abiding and Trustworthy Enterprise" and other honorary titles.
Chinese patent medicine industry
The company has always adhered to the corporate tenet of "cultivating people with quality and brewing medicine with virtue", adhered to the business philosophy of "sincerity, sincerity and purity", aimed at the modernization of traditional Chinese medicine, and took caring for human health as its own responsibility. The company has 12 major drug dosage forms, 205 drug approval numbers, 5 exclusive varieties, 8 high-quality and high-price drugs, and 3 national second-class protected drugs of traditional Chinese medicine. The company has 48 drugs with drug approval numbers included in the National Essential Medicines List, and 128 drugs with drug approval numbers listed in the National Medical Insurance Catalog (2017 edition). The company's main Chinese patent medicine products include Simiao Pills, Huoqi Tablets, Kidney Rehabilitation Capsules, Huoxue Tongmai Tablets, Radix Fenqing Pills, Neixiao Scrofula Pills, Erding Granules, Pediatric Baibei Cough Syrup, Haibei Gastric Ulcer Capsules, etc. The company cooperates with nearly 5,000 medical institutions at all levels and more than 1,000 large pharmaceutical distribution companies in the country in the sales of prescription drugs, and has established a strong and stable sales network in the country. In July 2015, the company established the OTC division. As of 2016, the OTC control and sales team has built nearly 3,000 people, realized nearly 50,000 terminal cooperation, and shipped nearly 8 million boxes in total, laying the dominant position of Erding granules, pediatric Baibei cough syrup and other products, forming a good situation in which prescription drug sales and OTC control and sales go hand in hand and brand sharing.
Ginseng industry
In 2010, in response to the call of the Jilin Provincial Party Committee and the Provincial Government, the company took advantage of the great opportunity of ginseng "medicine and food homology" to enter the ginseng industry, with a total investment of nearly 2 billion yuan, and established four ginseng production and processing bases around the main ginseng producing areas in Jilin Province. At present, the four major ginseng production and processing bases have obtained GMP certification and have fully entered the formal production and operation stage, which has greatly improved the company's labor capacity.
Holding high the banner of "scientific and technological ginseng", the company has established two high-tech R&D institutions, Zixin Ginseng R&D Co., Ltd. and Zixin Pharmaceutical Research Co., Ltd., which constitute an international leading R&D force led by experts and scholars, with doctors and masters as the backbone, and established a stepped scientific research system of "production generation, reserve generation and development generation", and strive to create "quality ginseng and scientific and technological ginseng". Zixin ginseng products have a complete structure and rich categories, and have developed more than 500 kinds of products, including food, health care products and cosmetics, of which more than 100 kinds of products have been approved by the state for the production of "medicine and food homology", and the number of registered products ranks first among domestic industrial enterprises. The company is striving to build a leading brand in the Chinese ginseng industry, steadily implementing the brand strategy of "the world ginseng looks at China, and the Chinese look at Zixin" to help revitalize the Chinese ginseng industry.
Gene sequencer industry
In 2013, the company began to lay out the gene sequencer industry. The R&D, production and sales of gene sequencers and supporting reagents are the company's current vigorous development business. In order to develop gene sequencing projects, the company has established Jilin Zhongke Zixin Technology Co., Ltd., Beijing Zhongke Zixin Technology Co., Ltd., and Dunhua Zhongke Zixin Technology Co., Ltd. The domestic second-generation high-throughput DNA sequencer BIGIS product independently developed by the company is currently the first domestic second-generation sequencer that meets or partially exceeds the technical indicators of international mainstream equipment, with the advantages of high throughput, high read length and high accuracy, and the cost is less than 1/2 of the imported equipment, and the application cost is more than 1/3 of the imported equipment. The full integration of gene sequencer and traditional Chinese medicine diagnosis and treatment can successfully create "precision traditional Chinese medicine". This is not only an important measure for the company to use "genes" to shape its core competitiveness, but also its own innovation and upgrading in the context of the "Healthy China" policy.
At present, the development of the company's three major industries of Chinese patent medicine, ginseng and gene sequencer is in full swing. In the future, the company will realize the big health industry ecosystem with "scientific and technological innovation" as its core competitiveness, and strive to forge ahead towards the grand goal of "building a century-old Zixin and creating a national brand"!
